ClinicalTrials.gg
TerminatedNCT00452361Updated Sep 3, 2012Results posted

Study Evaluating of Calcineurin Inhibitors Versus Sirolimus in Renal Allograft Recipient

A Phase 4 interventional study of Sirolimus+MMF or MPS or AZA+Steroid and Calcineurin Inhibitors (either cyclosporine or tacrolimus)+MMF or MPS or AZA+Steroid in Kidney Transplantation, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer. Terminated at 1 site in Taiwan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-09-03.

Sponsored by Wyeth is now a wholly owned subsidiary of Pfizer (part of Pfizer) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
31
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study will evaluate whether conversion from cyclosporine, a calcineurin inhibitor (CI) to sirolimus (SRL) results in improved long-term renal function without a negative impact on safety or immunosuppressive efficacy, and to further examine the potential of SRL to reduce the severity and/or progression of chronic allograft nephropathy (CAN).

Read the detailed description

This open-label, randomized, parallel-group, comparative, outpatient study will be conducted in multiple centers in Taiwan.

The study will randomize approximately 120 patients. 80 patients will be randomized to the SRL therapy group (conversion from CI- to SRL-based immunosuppression: group A) and 40 patients to the CI therapy group (continued CI therapy: group B).

Dosage and Administration

SRL Therapy: At the time of randomization on day 1, each patient will have been receiving:

  • triple therapy with a CI (tacrolimus or CsA) that began at the time of transplantation or within 2 weeks thereafter AND
  • corticosteroids corresponding to a dosage range of 2.5 to 15 mg/day for prednisone or prednisolone (2 to 12 mg/day for methylprednisolone) or the alternate day equivalent for at least 12 weeks before randomization, PLUS
  • either MMF (minimum dose 500 mg/day)/MPS (minimum dose 360 mg/day) or AZA (minimum dose 50 mg/day) for at least 12 weeks before randomization.

SRL will be added to the immunosuppressive regimen for Group A. Group B will continue on this CI immunosuppressive regimen.

02

Conditions studied

  • Kidney Transplantation
03

In context

Lead sponsor

Wyeth is now a wholly owned subsidiary of Pfizer is the lead sponsor of 484 studies on the registry; none are open to participants now.

First submitted before Wyeth became part of Pfizer.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects must be at least 18 years of age.
  • Subjects who are 6 to 60 months after renal transplantation.
  • Subjects who have a stable graft function.

Exclusion criteria

Exclusion Criteria:

  • Subjects with active major infection, including , decreased , elevated lipids, or multiple organ transplants.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
31 participants (actual)

Study arms

  • Experimental
    1

    Sirolimus therapy

    Drug: Sirolimus+MMF or MPS or AZA+Steroid

  • Active comparator
    2

    Calcineurin Inhibitor therapy (either cyclosporine or tacrolimus)

    Drug: Calcineurin Inhibitors (either cyclosporine or tacrolimus)+MMF or MPS or AZA+Steroid

Interventions

  • DrugSirolimus+MMF or MPS or AZA+Steroid

    Corticosteroids will be administered according to local practice, within a daily maintenance dosage range of 2.5 to15 mg for prednisone or prednisolone (2 to 12 mg/day for methylprednisolone) or the alternate day equivalent.

  • DrugCalcineurin Inhibitors (either cyclosporine or tacrolimus)+MMF or MPS or AZA+Steroid

    The maintenance dose of: 1. MMF will not exceed 1500 mg/day or PMS will not exceed 1080 mg/day 2. AZA will not exceed 75 mg/day Thereafter, at the discretion of the investigator, MMF/MPS or AZA may be: 1. continued for the entire 104-week period of randomized therapy 2. subsequently discontinued 3. restarted after discontinuation

06

What researchers measure

Primary outcomes

  1. Change in Glomerular Filtration Rate (GFR) Change From Baseline

    GFR is an index of kidney function. GFR describes the flow rate of filtered fluid through the kidney. GFR can be measured directly or estimated using established formulas. GFR was calculated using Nankivell formula. A normal GFR is \> 90 mL/min, although children and older people usually have a lower GFR. Lower values indicate poor kidney function. A GFR \<15 is consistent with kidney failure.

    Time frame: 104 weeks

Secondary outcomes

  1. Change in Glomerular Filtration Rate (GFR)

    GFR is an index of kidney function. GFR describes the flow rate of filtered fluid through the kidney. GFR can be measured directly or estimated using established formulas. GFR was calculated using Nankivell formula. A normal GFR is \> 90 mL/min, although children and older people usually have a lower GFR. Lower values indicate poor kidney function. A GFR \<15 is consistent with kidney failure.

    Time frame: Baseline and Week 24

  2. Change in Glomerular Filtration Rate (GFR)

    GFR is an index of kidney function. GFR describes the flow rate of filtered fluid through the kidney. GFR can be measured directly or estimated using established formulas. GFR was calculated using Nankivell formula. A normal GFR is \> 90 mL/min, although children and older people usually have a lower GFR. Lower values indicate poor kidney function. A GFR \<15 is consistent with kidney failure.

    Time frame: Baseline and Week 52

  3. Change in Glomerular Filtration Rate (GFR)

    GFR is an index of kidney function. GFR describes the flow rate of filtered fluid through the kidney. GFR can be measured directly or estimated using established formulas. GFR was calculated using Nankivell formula. A normal GFR is \> 90 mL/min, although children and older people usually have a lower GFR. Lower values indicate poor kidney function. A GFR \<15 is consistent with kidney failure.

    Time frame: Baseline and Week 104

  4. Patient and Graft Survival

    Patient survival defined as participants living with or without a functioning graft. Graft survival defined as those participants who did not experience graft loss. Graft loss defined as physical loss (nephrectomy), functional loss (necessitating maintenance dialysis for \>8 weeks), retransplant or death during the first 12 months after randomization.

    Time frame: Week 24

  5. Patient and Graft Survival

    Patient survival defined as participants living with or without a functioning graft. Graft survival defined as those participants who did not experience graft loss. Graft loss defined as physical loss (nephrectomy), functional loss (necessitating maintenance dialysis for \>8 weeks), retransplant or death during the first 12 months after randomization.

    Time frame: Week 52

  6. Patient and Graft Survival

    Patient survival defined as participants living with or without a functioning graft. Graft survival defined as those participants who did not experience graft loss. Graft loss defined as physical loss (nephrectomy), functional loss (necessitating maintenance dialysis for \>8 weeks), retransplant or death during the first 12 months after randomization.

    Time frame: Week 104

  7. Change From Baseline in Diastolic Blood Pressure at Week 24

    Value at Week 24 minus value at baseline.

    Time frame: Baseline and Week 24

  8. Change From Baseline in Diastolic Blood Pressure at Week 52

    Value at Week 52 minus value at baseline.

    Time frame: Baseline and Week 52

  9. Change From Baseline in Diastolic Blood Pressure at Week 104

    Value at Week 104 minus value at baseline.

    Time frame: Baseline and Week 104

  10. Change From Baseline in Systolic Blood Pressure at Week 24

    Value at Week 24 minus value at baseline.

    Time frame: Baseline and Week 24

  11. Change From Baseline in Systolic Blood Pressure at Week 52

    Value at Week 52 minus value at baseline.

    Time frame: Baseline and Week 52

  12. Change From Baseline in Systolic Blood Pressure at Week 104

    Value at Week 104 minus value at baseline.

    Time frame: Baseline and Week 104

  13. Change From Baseline in the Severity and Progression of Biopsy-Confirmed Chronic Allograft Nephropathy (CAN) at Week 104

    Time frame: Baseline and Week 104

  14. Occurence of Acute Rejection or Premature Withdrawal From Study Medication for Any Reason by Week 52

    Time frame: Weeks 52

  15. Occurence of Acute Rejection or Premature Withdrawal From Study Medication for Any Reason by Week 104

    Time frame: Week 104

  16. Incidence and Severity of Biopsy-Confirmed Acute Rejection at Week 24

    Time frame: Week 24

  17. Incidence and Severity of Biopsy-Confirmed Acute Rejection at Week 52

    Time frame: Week 52

  18. Incidence and Severity of Biopsy-Confirmed Acute Rejection at Week 104

    Time frame: Week 104

07

Results

Posted Sep 3, 2012
Limitations and caveats
Study terminated early due to difficulties in enrolling qualified patients. No patients completed 104 weeks (primary outcome); a few completed 60 weeks. Insufficient data were available for efficacy analyses.

Participant flow

Patients were recruited in Taiwan from April 2007 to May 2008.

Participant flow — Overall Study
MilestoneSirolimus (SRL)Calcineurin Inhibitor (CI)
Started2110
Completed00
Not completed2110
Withdrew: Adverse event80
Withdrew: Withdrawal by subject01
Withdrew: Premature termination139

Outcome measures

PrimaryChange in Glomerular Filtration Rate (GFR) Change From Baseline

GFR is an index of kidney function. GFR describes the flow rate of filtered fluid through the kidney. GFR can be measured directly or estimated using established formulas. GFR was calculated using Nankivell formula. A normal GFR is \> 90 mL/min, although children and older people usually have a lower GFR. Lower values indicate poor kidney function. A GFR \<15 is consistent with kidney failure.

Time frame:
104 weeks

No measurements were reported for this outcome.

SecondaryChange in Glomerular Filtration Rate (GFR)

GFR is an index of kidney function. GFR describes the flow rate of filtered fluid through the kidney. GFR can be measured directly or estimated using established formulas. GFR was calculated using Nankivell formula. A normal GFR is \> 90 mL/min, although children and older people usually have a lower GFR. Lower values indicate poor kidney function. A GFR \<15 is consistent with kidney failure.

Time frame:
Baseline and Week 24

No measurements were reported for this outcome.

SecondaryChange in Glomerular Filtration Rate (GFR)

GFR is an index of kidney function. GFR describes the flow rate of filtered fluid through the kidney. GFR can be measured directly or estimated using established formulas. GFR was calculated using Nankivell formula. A normal GFR is \> 90 mL/min, although children and older people usually have a lower GFR. Lower values indicate poor kidney function. A GFR \<15 is consistent with kidney failure.

Time frame:
Baseline and Week 52

No measurements were reported for this outcome.

SecondaryChange in Glomerular Filtration Rate (GFR)

GFR is an index of kidney function. GFR describes the flow rate of filtered fluid through the kidney. GFR can be measured directly or estimated using established formulas. GFR was calculated using Nankivell formula. A normal GFR is \> 90 mL/min, although children and older people usually have a lower GFR. Lower values indicate poor kidney function. A GFR \<15 is consistent with kidney failure.

Time frame:
Baseline and Week 104

No measurements were reported for this outcome.

SecondaryPatient and Graft Survival

Patient survival defined as participants living with or without a functioning graft. Graft survival defined as those participants who did not experience graft loss. Graft loss defined as physical loss (nephrectomy), functional loss (necessitating maintenance dialysis for \>8 weeks), retransplant or death during the first 12 months after randomization.

Time frame:
Week 24

No measurements were reported for this outcome.

SecondaryPatient and Graft Survival

Patient survival defined as participants living with or without a functioning graft. Graft survival defined as those participants who did not experience graft loss. Graft loss defined as physical loss (nephrectomy), functional loss (necessitating maintenance dialysis for \>8 weeks), retransplant or death during the first 12 months after randomization.

Time frame:
Week 52

No measurements were reported for this outcome.

SecondaryPatient and Graft Survival

Patient survival defined as participants living with or without a functioning graft. Graft survival defined as those participants who did not experience graft loss. Graft loss defined as physical loss (nephrectomy), functional loss (necessitating maintenance dialysis for \>8 weeks), retransplant or death during the first 12 months after randomization.

Time frame:
Week 104

No measurements were reported for this outcome.

SecondaryChange From Baseline in Diastolic Blood Pressure at Week 24

Value at Week 24 minus value at baseline.

Time frame:
Baseline and Week 24

No measurements were reported for this outcome.

SecondaryChange From Baseline in Diastolic Blood Pressure at Week 52

Value at Week 52 minus value at baseline.

Time frame:
Baseline and Week 52

No measurements were reported for this outcome.

SecondaryChange From Baseline in Diastolic Blood Pressure at Week 104

Value at Week 104 minus value at baseline.

Time frame:
Baseline and Week 104

No measurements were reported for this outcome.

SecondaryChange From Baseline in Systolic Blood Pressure at Week 24

Value at Week 24 minus value at baseline.

Time frame:
Baseline and Week 24

No measurements were reported for this outcome.

SecondaryChange From Baseline in Systolic Blood Pressure at Week 52

Value at Week 52 minus value at baseline.

Time frame:
Baseline and Week 52

No measurements were reported for this outcome.

SecondaryChange From Baseline in Systolic Blood Pressure at Week 104

Value at Week 104 minus value at baseline.

Time frame:
Baseline and Week 104

No measurements were reported for this outcome.

SecondaryChange From Baseline in the Severity and Progression of Biopsy-Confirmed Chronic Allograft Nephropathy (CAN) at Week 104
Time frame:
Baseline and Week 104

No measurements were reported for this outcome.

SecondaryOccurence of Acute Rejection or Premature Withdrawal From Study Medication for Any Reason by Week 52
Time frame:
Weeks 52

No measurements were reported for this outcome.

SecondaryOccurence of Acute Rejection or Premature Withdrawal From Study Medication for Any Reason by Week 104
Time frame:
Week 104

No measurements were reported for this outcome.

SecondaryIncidence and Severity of Biopsy-Confirmed Acute Rejection at Week 24
Time frame:
Week 24

No measurements were reported for this outcome.

SecondaryIncidence and Severity of Biopsy-Confirmed Acute Rejection at Week 52
Time frame:
Week 52

No measurements were reported for this outcome.

SecondaryIncidence and Severity of Biopsy-Confirmed Acute Rejection at Week 104
Time frame:
Week 104

No measurements were reported for this outcome.

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Sirolimus (SRL)—6/21 (28.6%)78/21 (371.4%)
Calcineurin Inhibitor (CI)—2/10 (20%)18/10 (180%)
Most frequent serious events
Most frequent serious events
EventSirolimus (SRL)Calcineurin Inhibitor (CI)
Lens dislocationEye disorders0/211/10
AppendicitisGastrointestinal disorders0/211/10
PneumonitisRespiratory, thoracic and mediastinal disorders2/210/10
Mechanical ileusGastrointestinal disorders1/210/10
PyrexiaGeneral disorders1/210/10
CellulitisGeneral disorders1/210/10
Pharyngolaryngeal painRespiratory, thoracic and mediastinal disorders1/210/10
Most frequent other events
Showing 10 of 20
Most frequent other events
EventSirolimus (SRL)Calcineurin Inhibitor (CI)
Upper respiratory tract infectionRespiratory, thoracic and mediastinal disorders11/216/10
Mouth ulcerationGastrointestinal disorders11/212/10
HyperlipidaemiaMetabolism and nutrition disorders10/213/10
AcneSkin and subcutaneous tissue disorders8/211/10
CoughRespiratory, thoracic and mediastinal disorders7/211/10
HyperuricaemiaMetabolism and nutrition disorders2/213/10
DiarrhoeaGastrointestinal disorders3/212/10
ArthralgiaMusculoskeletal and connective tissue disorders4/210/10
Hepatic function abnormalHepatobiliary disorders3/210/10
InsominaNervous system disorders3/210/10

Baseline characteristics

Age Continuous
Age Continuous(years)Sirolimus (SRL)Calcineurin Inhibitor (CI)Total
Mean46.8 ± 7.942.2 ± 13.943.3 ± 10.2
Sex: Female, Male
Sex: Female, Male(Participants)Sirolimus (SRL)Calcineurin Inhibitor (CI)Total
Female11213
Male10818
08

Study locations

1 site
  • Select Cities, Taiwan
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2007, a primary completion of Aug 2008 and a completion of Aug 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2012, 4 years 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 23, 2007
First posted
Mar 27, 2007
Start
Apr 2007
Primary completionActual
Aug 2008
CompletionActual
Aug 2008
Results first posted
Sep 3, 2012
Last update
Sep 3, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 3, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00452361
Responsible party
Sponsor
First posted
Mar 27, 2007
Start date
Apr 2007
Primary completion
Aug 2008
Completion
Aug 2008
Results posted
Sep 3, 2012
Last update
Sep 3, 2012

Study contacts

Medical Monitor
study director · Wyeth is now a wholly owned subsidiary of Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jul 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion